The combination of fianlimab and cemiplimab showed a similar safety profile to anti-PD-1 monotherapy except for adrenal insufficiency, which was slightly increased by 10.4%, and in turn, is comparable to the observed rate under dual checkpoint inhibition with anti-PD-1 and anti-CTLA-4. Here, PDCD1 is linked to Adrenal insufficiency.